Surgery Partners (SGRY) Stock Forecast & Price Target

Compare

360 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

SGRY Analyst Ratings

Moderate Buy

8 Buy

3 Hold

0 Sell

Based on 11 analysts giving stock ratings to

Surgery

Partners

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

SGRY Stock 12 Month Forecast

Average Price Target

$30.70

▲(34.65% Upside)

Based on 11 Wall Street analysts offering 12 month price targets for Surgery Partners in the last 3 months. The average price target is $30.70 with a high forecast of $36.00 and a low forecast of $24.00. The average price target represents a 34.65% change from the last price of $22.80.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"20":"$20","37":"$37","24.25":"$24.3","28.5":"$28.5","32.75":"$32.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":36,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$36.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30.7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$30.70</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$24.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[20,24.25,28.5,32.75,37],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.28,22.412307692307692,23.544615384615387,24.676923076923078,25.80923076923077,26.941538461538464,28.073846153846155,29.206153846153846,30.338461538461537,31.470769230769232,32.60307692307693,33.73538461538462,34.86769230769231,{"y":36,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.28,22.004615384615384,22.72923076923077,23.453846153846154,24.17846153846154,24.903076923076924,25.627692307692307,26.35230769230769,27.076923076923077,27.801538461538463,28.526153846153846,29.25076923076923,29.975384615384613,{"y":30.7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.28,21.48923076923077,21.69846153846154,21.907692307692308,22.11692307692308,22.326153846153847,22.535384615384615,22.744615384615386,22.953846153846154,23.163076923076922,23.372307692307693,23.58153846153846,23.790769230769232,{"y":24,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":30.22,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.95,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.49,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.75,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.81,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.17,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.49,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.08,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.48,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.43,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.39,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.55,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.28,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$36.00

Average Price Target$30.70

Lowest Price Target$24.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Rosa Clinessa

TR | OpenAI - 4o

$23→$25

Hold

9.65%

Upside

Reiterated

08/14/25

AI Generated ArticleAI Generated Article

Andrew Mok CFA

Barclays

$24

Hold

5.26%

Upside

Reiterated

08/07/25

Barclays Reaffirms Their Hold Rating on Surgery Partners (SGRY)

Ben Hendrix

RBC Capital

$35

Buy

53.51%

Upside

Reiterated

08/06/25

Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (NASDAQ: EYPT), NewAmsterdam Pharma Company (NASDAQ: NAMS) and Surgery Partners (NASDAQ: SGRY)

Whit Mayo

Leerink Partners

$34

Buy

49.12%

Upside

Reiterated

08/06/25

Leerink Partners Reaffirms Their Buy Rating on Surgery Partners (SGRY)

Bill Sutherland

Benchmark Co.

$35

Buy

53.51%

Upside

Reiterated

08/06/25

Surgery Partners: Strategic Positioning and Financial Performance Drive Buy Rating Amid Macroeconomic Challenges

Ryan Langston

TD Cowen

$28

Buy

22.81%

Upside

Reiterated

08/05/25

2:37:39 AM (UTC+02:00) Ben Yoffe Subject: SGRY - 2Q25 Model Update - TD Cowen SURGERY PARTNERS (NASDAQ: SGRY) Buy (1) ESG $28.00 2Q25 MODEL UPDATE THE TD COWEN INSIGHT SGRY posted a slight +1% EBITDA beat vs consensus with SS Cases +3.4% and SS revs/case +1.6% yty, with SWB and supplies better than cons as a % of revs. SGRY expects to hit their $200m M&A target spend, though timing drives FY25 EBITDA expectations potentially toward the lower end of the reiterated FY range.

Joanna Gajuk

Bank of America Securities

$28

Buy

22.81%

Upside

Upgraded

07/28/25

Surgery Partners upgraded to Buy from Neutral at BofASurgery Partners upgraded to Buy from Neutral at BofA

Sarah James

Cantor Fitzgerald

$36

Buy

57.89%

Upside

Reiterated

07/02/25

Surgery Partners (SGRY) Receives a Buy from Cantor Fitzgerald

A.J. Rice

UBS

$34

Buy

49.12%

Upside

Reiterated

06/24/25

UBS Keeps Their Buy Rating on Surgery Partners (SGRY)

Ann Hynes

Mizuho Securities

$28

Buy

22.81%

Upside

Reiterated

06/17/25

Mizuho Securities Reaffirms Their Buy Rating on Surgery Partners (SGRY)

Matthew Gillmor CFA

KeyBanc

―

Hold

―

Reiterated

05/19/25

KeyBanc reiterates Sector Weight Rating on Surgery Partners (SGRY)KeyBanc analyst Matthew Gillmor reiterated a Sector Weight rating and {REMOVEPT} price target on Surgery Partners (NASDAQ: SGRY).

Lisa Gill

J.P. Morgan

$28→$27

Hold

18.42%

Upside

Reiterated

05/16/25

Surgery Partners (SGRY) PT Lowered to $27 at JPMorganJPMorgan analyst Lida Gill lowered the price target on Surgery Partners (NASDAQ: SGRY) to $27.00 (from $28.00) while maintaining a Neutral rating.

Brian Tanquilut

Jefferies

$31

Buy

35.96%

Upside

Reiterated

03/03/25

Buy Rating for Surgery Partners: Strong Revenue Growth, Strategic Developments, and Market Opportunities

Tao Qiu

Macquarie

―

Buy

―

Reiterated

11/19/24

Overreaction to Selloff: Surgery Partners' Undervalued Opportunity Amidst Strong Fundamentals

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Rosa Clinessa

TR | OpenAI - 4o

$23→$25

Hold

9.65%

Upside

Reiterated

08/14/25

AI Generated ArticleAI Generated Article

Andrew Mok CFA

Barclays

$24

Hold

5.26%

Upside

Reiterated

08/07/25

Barclays Reaffirms Their Hold Rating on Surgery Partners (SGRY)

Ben Hendrix

RBC Capital

$35

Buy

53.51%

Upside

Reiterated

08/06/25

Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (NASDAQ: EYPT), NewAmsterdam Pharma Company (NASDAQ: NAMS) and Surgery Partners (NASDAQ: SGRY)

Whit Mayo

Leerink Partners

$34

Buy

49.12%

Upside

Reiterated

08/06/25

Leerink Partners Reaffirms Their Buy Rating on Surgery Partners (SGRY)

Bill Sutherland

Benchmark Co.

$35

Buy

53.51%

Upside

Reiterated

08/06/25

Surgery Partners: Strategic Positioning and Financial Performance Drive Buy Rating Amid Macroeconomic Challenges

Ryan Langston

TD Cowen

$28

Buy

22.81%

Upside

Reiterated

08/05/25

Joanna Gajuk

Bank of America Securities

$28

Buy

22.81%

Upside

Upgraded

07/28/25

Surgery Partners upgraded to Buy from Neutral at BofASurgery Partners upgraded to Buy from Neutral at BofA

Sarah James

Cantor Fitzgerald

$36

Buy

57.89%

Upside

Reiterated

07/02/25

Surgery Partners (SGRY) Receives a Buy from Cantor Fitzgerald

A.J. Rice

UBS

$34

Buy

49.12%

Upside

Reiterated

06/24/25

UBS Keeps Their Buy Rating on Surgery Partners (SGRY)

Ann Hynes

Mizuho Securities

$28

Buy

22.81%

Upside

Reiterated

06/17/25

Mizuho Securities Reaffirms Their Buy Rating on Surgery Partners (SGRY)

Matthew Gillmor CFA

KeyBanc

―

Hold

―

Reiterated

05/19/25

KeyBanc reiterates Sector Weight Rating on Surgery Partners (SGRY)KeyBanc analyst Matthew Gillmor reiterated a Sector Weight rating and {REMOVEPT} price target on Surgery Partners (NASDAQ: SGRY).

Lisa Gill

J.P. Morgan

$28→$27

Hold

18.42%

Upside

Reiterated

05/16/25

Surgery Partners (SGRY) PT Lowered to $27 at JPMorganJPMorgan analyst Lida Gill lowered the price target on Surgery Partners (NASDAQ: SGRY) to $27.00 (from $28.00) while maintaining a Neutral rating.

Brian Tanquilut

Jefferies

$31

Buy

35.96%

Upside

Reiterated

03/03/25

Buy Rating for Surgery Partners: Strong Revenue Growth, Strategic Developments, and Market Opportunities

Tao Qiu

Macquarie

―

Buy

―

Reiterated

11/19/24

Overreaction to Selloff: Surgery Partners' Undervalued Opportunity Amidst Strong Fundamentals

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Surgery Partners

1 Month

xxx

Success Rate

16/26 ratings generated profit

Average Return

+2.67%

reiterated a xxx

rating 11 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 61.54% of your transactions generating a profit, with an average return of +2.67% per trade.

3 Months

xxx

Success Rate

16/26 ratings generated profit

Average Return

+1.60%

reiterated a xxx

rating 11 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 61.54% of your transactions generating a profit, with an average return of +1.60% per trade.

1 Year

Brian TanquilutJefferies

Success Rate

11/26 ratings generated profit

Average Return

+14.89%

reiterated a buy rating 6 months ago

Copying Brian Tanquilut's trades and holding each position for 1 Year would result in 42.31% of your transactions generating a profit, with an average return of +14.89% per trade.

2 Years

xxx

Success Rate

7/26 ratings generated profit

Average Return

-2.33%

reiterated a xxx

rating 11 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 26.92% of your transactions generating a profit, with an average return of -2.33% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SGRY Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, SGRY has received 15 Buy Ratings, 15 Hold Ratings, and 0 Sell Ratings. SGRY average Analyst price target in the past 3 months is 30.70.

Each month's total comprises the sum of three months' worth of ratings.

SGRY Financial Forecast

SGRY Earnings Forecast

Next quarter’s earnings estimate for SGRY is $0.21 with a range of $0.16 to $0.25. The previous quarter’s EPS was $0.17. SGRY beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.26% of the time in the same period. In the last calendar year SGRY has Outperformed its overall industry.

SGRY Sales Forecast

Next quarter’s sales forecast for SGRY is $823.86M with a range of $803.80M to $839.40M. The previous quarter’s sales results were $826.20M. SGRY beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.42% of the time in the same period. In the last calendar year SGRY has Outperformed its overall industry.

SGRY Stock Forecast FAQ

What is SGRY’s average 12-month price target, according to analysts?

Based on analyst ratings, Surgery Partners Inc’s 12-month average price target is 30.70.

What is SGRY’s upside potential, based on the analysts’ average price target?

Surgery Partners Inc has 34.65% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is SGRY a Buy, Sell or Hold?

Surgery Partners Inc has a consensus rating of Moderate Buy which is based on 8 buy ratings, 3 hold ratings and 0 sell ratings.

What is Surgery Partners Inc’s price target?

The average price target for Surgery Partners Inc is 30.70. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $36.00 ,the lowest forecast is $24.00. The average price target represents 34.65% Increase from the current price of $22.8.

What do analysts say about Surgery Partners Inc?

Surgery Partners Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of SGRY?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Surgery Partners (SGRY) Stock Forecast & Price Target

SGRY Analyst Ratings

SGRY Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Surgery Partners

SGRY Analyst Recommendation Trends

SGRY Financial Forecast

SGRY Earnings Forecast

SGRY Sales Forecast

SGRY Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts